News Update

Biotech Collaborates to Advance Psychedelics Use in Cancer, Other Applications

News Update
  ()
Revive Therapeutics enters an agreement with PharmaTher, a specialty psychedelics pharmaceutical firm. read more >

Precision BioSciences & Eli Lilly Partner to Develop In Vivo Therapies for Genetic Disorders

  ()
Precision BioSciences shares traded 13% higher after the company reported it is partnering with Eli Lilly & Co. to develop in vivo therapies for genetic disorders with an initial focus on Duchenne's muscular dystrophy and two other undisclosed gene targets. read more >

Corcept Therapeutics Shares Rise 25% on Favorable U.S. Patent Office Ruling

  ()
Shares of Corcept Therapeutics reached a new 52-week high after the firm reported that the U.S. Patent Trial and Appeals Board affirmed that all claims pertaining to its U.S. Patent No.10,195,214 are valid. read more >

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering

  ()
Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock. The report came one day after the firm advised it had completed enrollment of its Phase 2b/3 Pivotal DAZZLE Study of KSI-301 in patients with wet age-related macular degeneration. read more >

Psychedelic Company Expected to Begin Trading Nov. 18

Reverse Takeover
  ()
Delic Corp., a thought leader in psychedelics, will trade on the Canadian Securities Exchange. read more >

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies

  ()
Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits. read more >

Moderna Shares Get a Boost from Phase 3 COVID-19 Vaccine Trial Data Demonstrating 94.5% Efficacy

  ()
Moderna shares traded 10% higher to a new 52-week high after the company reported its COVID-19 vaccine candidate, mRNA-1273, met its primary endpoint in the first interim analysis of the Phase 3 COVE Study by achieving an efficacy rate of 94.5%. read more >
News Update

Life Sciences Firm Completes Development of Dissolvable Oral Psilocybin

News Update
  ()
Revive Therapeutics reported that it has developed an oral thin-film strip psilocybin product with doses ranging from 1 to 20 milligrams. read more >

Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer

  ()
Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash. read more >
News Update

Biotech Involved in COVID-19, Neurodegenerative Diseases Reports Q3/20 Results

News Update
  ()
ProMIS Neurosciences formed two new joint ventures, one for developing tests for the detection, diagnosis and monitoring of Alzheimer's disease, and the second for serological assays for antibodies to the SARS-CoV-2 virus. read more >

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic

Research Report
  ()
Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report. read more >

Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial

  ()
Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer. read more >
News Update

Biotech Comments on FDA Advisory Committee Recommendation of Not Licensing Alzheimer's Drug

News Update
  ()
ProMIS Neurosciences, which is developing its own therapeutics for this disease, weighs in on the committee's conclusions regarding Biogen's aducanumab. read more >

Expert Investing Ideas

"SPR is the number one cannabis stock to own today."

–Cynthia Berryman, Financial News Now


"We expect PMN to forge a licensing deal in Q2/19 or Q3/19."

–André Uddin, Mackie Research Capital



Recommendation for The Life Sciences Report Readers

Be the First to Hear Direct from the Experts…Live and in Real Time!

StreetSmart Live! Was founded by the same team that that brought you The Life Sciences Report.

Subscribe to the StreetSmart Live! YouTube channel and be the first to hear about interesting investment ideas live and in real time... straight from the experts. This type of intellectual capital is usually not made available to the general public, but StreetSmart Live! is your "In."

Subscribe Now (It's Free)

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
Last StreetSmart Live! Show
NASDAQ Biotech ARCA Pharmaceutical
News Update

Biotech Plans to Release Interim Data for Phase 2b/3 COVID-19 Trial in December

News Update
  ()
Algernon Pharmaceuticals reported it intends to announce the interim results from its Ifenprodil Phase 2b/3 COVID-19 human study during the first week of December 2020. read more >

Individuals Succeed Using This Digital Therapy—Now It's Moving to Insurers

Contributed Opinion
  ()
Independent financial analyst Matt Badiali profiles a digital therapeutics company that is changing diabetes treatment. read more >

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned

  ()
Pfizer shares traded 9% higher to a new 52-week high price after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection. The company is making plans to produce up to 1.3 billion vaccine doses in 2021. read more >